biologics
GBMA welcomes PBS listing of infliximab
The inclusion of the first monoclonal antibody biosimilar on the PBS will deliver immediate savings to the Federal Government; however the full potential of this and other biosimilar medicines relies …
Inflectra to be PBS listed from December
Pfizer today confirmed that the first mAb biosimilar, Inflectra (infliximab), will be added to the PBS on 1 December 2015 for the treatment of eight inflammatory conditions.
Call for feedback on biosimilars awareness project
The Department of Health is seeking feedback on the Implementation Framework for the Biosimilars Awareness project. The Department of Health says the aim of the project is improve awareness and …
High Court decision could undermine development of innovative medicines
The High Court decision to disallow patenting of isolated genetic materials is a worry for the innovative medicines sector, says Medicines Australia. “It is essential that Australia maintains strong and …
Medicines Australia disappointed by TPP outcomes
The outcomes of the negotiations for the Trans-Pacific Partnership agreed to in Atlanta overnight are a disappointing outcome and a missed opportunity to stimulate and grow the Australian biopharmaceutical industry, …
Major concerns remain with Trans Pacific Partnership: PHAA
The conclusion of the Trans Pacific Partnership was announced last night with some welcome news for Australian health advocates, but major concerns remain, says the Public Health Association of Australia. …
PSA seeks consensus document on biological medicines
The PSA has released its position statement on biologics, stating that it believes a consensus Australian document on terminology and definitions relating to biological medicines, including biosimilar medicines, should be …
First in new biologics class to treat psoriasis
The first in a new class of biologic medicine that acts to interrupt the inflammatory cycle and help clear the skin of patients with moderate-to-severe psoriasis has been added to the PBS from September 1, 2015.
GBMA welcomes the ‘a’ flagging of biosimilar infliximab
The Generic and Biosimilar Medicines Association has welcomes the recommendation by the PBAC to list biosimilar infliximab (Inflectra) on the PBS and to recommend the marking as equivalent, also known …
‘A’ flagging has Medicines Australia concerned
Medicines Australia has expressed concern about the PBAC’s recommendation that pharmacists be allowed to substitute the biosimilars in place of biologic medicines prescribed by a patient’s doctor. “The so-called ‘a-flagging’ …
GBMA welcomes infliximab biosimilar listing
The Generic and Biosimilar Medicines Association has welcomed the approval of biosimilar infliximab, Inflectra. Inflectra is the first biosimilar infliximab to be approved in Australia, providing an alternative, affordable treatment …
Lives at stake if Trans Pacific Partnership means meds price rise
As trade ministers meet in Hawaii on 28-31 July in an effort to finalise the Trans Pacific Partnership, the Public Health Association of Australia and other stakeholders say that lives …